Title title title here

AUTHOR NAME

Text intro bold text intro

  • Read the quick summary:
    • Advancements in molecular prognostication have improved survival for metastatic spine disease patients through molecular prognostication and targeted therapies.
    • Key molecular markers EGFR, HER2, and BRAF mutations improve survival rates in lung, breast, and melanoma cancers with targeted therapies.
    • Clinical practice integration of the NOMS framework enhances decision-making by incorporating molecular markers and targeted therapies.

Disclaimer: The article represents the opinion of individual authors exclusively and not necessarily the opinion of AO or its clinical divisions.


Text text part 1 Text 1

Text 2 text text 2

Text 3 Text text 3 here

Text 4 here Text 4

About the authors:

Author 1 Bio here
Author 2 Bio here - if not needed delete this Splitter Row
Author 3 Bio here - if not needed delete this Splitter Row

References and further reading:

  1. Reference 1
  2. Referebce 2
  3. Reference 3